NeoGenomics, Inc. (NEO)

NASDAQ: NEO · IEX Real-Time Price · USD
8.34
-0.53 (-5.98%)
At close: Sep 27, 2022 4:00 PM
8.19
-0.15 (-1.80%)
After-hours: Sep 27, 2022 4:51 PM EDT
-5.98%
Market Cap 1.05B
Revenue (ttm) 489.31M
Net Income (ttm) -146.82M
Shares Out 125.80M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE 222.22
Dividend n/a
Ex-Dividend Date n/a
Volume 702,079
Open 9.04
Previous Close 8.87
Day's Range 8.23 - 9.05
52-Week Range 6.85 - 54.74
Beta 0.93
Analysts Buy
Price Target 18.36 (+120.1%)
Earnings Date Nov 2, 2022

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence ... [Read more...]

Industry Life Sciences Tools & Services
IPO Date Nov 2, 1999
Employees 2,000
Stock Exchange NASDAQ
Ticker Symbol NEO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 120.14% from the latest price.

Price Target
$18.36
(120.14% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Inivata and Collaborators to Present New Data to Support the Application of RaDaR™ MRD Assay Across Tumor Types at ES...

Inivata and Collaborators to Present New Data to Support the Application of RaDaR ™ MRD Assay Across Tumor Types at ESMO Congress 2022

2 weeks ago - GlobeNewsWire

NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022

Data Supports the Application of RaDaR™ MRD Assay Across Tumor Types Early Research on Potential Biomarker in Melanoma Patients Unresponsive to Immunotherapy FT. MYERS, FL / ACCESSWIRE / September 7, 20...

2 weeks ago - Accesswire

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FT. MYERS, FL / ACCESSWIRE / August 16, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, today announced, as required by the Nasdaq Li...

1 month ago - Accesswire

NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 27.27% and 0.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

NeoGenomics Reports Revenue of $125 Million in the Second Quarter

Second-Quarter 2022 Results and Highlights Consolidated revenue increased 3% to $125 million Clinical Services revenue increased 4% to $106 million Pharma Services revenue decreased 4% to $19 million Ch...

1 month ago - Accesswire

NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

NeoGenomics Announces Chief Executive Officer Appointment

Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board FT. MYERS, FL / ACCESSWIRE / July 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a...

2 months ago - Accesswire

NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022

FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to ...

2 months ago - Accesswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (N...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Compa...

3 months ago - Business Wire

NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?

NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

3 months ago - Zacks Investment Research

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of In...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) investors concerning the Company'...

3 months ago - Business Wire

The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO) on behalf of investors concerning the Compa...

3 months ago - Business Wire

Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Brea...

Inivata and Collaborators Announce New D ata Demonstrating Clinical Potential of its RaDa R™ MRD Test in HR + HER2- Breast Cancer

3 months ago - GlobeNewsWire

NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD...

FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms ...

3 months ago - Accesswire

Lost Money in NeoGenomics, Inc.?

OAKLAND, Calif.--(BUSINESS WIRE)---- $NEO #NEO--Gibbs Law Group is investigating potential legal claims on behalf of NEO investors.

3 months ago - Business Wire

NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences

FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced ...

3 months ago - Accesswire

NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory

CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D FORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology testing and g...

3 months ago - Accesswire

NeoGenomics Appoints Lynn Tetrault Interim CEO

FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, ...

4 months ago - Accesswire

Inivata and Collaborators to Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®...

Inivata and Collaborators to P resent New D ata F urther V alidat ing the A pplication of its RaDa R® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual Meeting

4 months ago - GlobeNewsWire

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of...

FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced ...

4 months ago - Accesswire

NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Iniv...

FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the app...

4 months ago - Accesswire

NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference

FT MYERS, FL / ACCESSWIRE / May 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced th...

4 months ago - Accesswire

NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

NeoGenomics Reports Revenue of $117 Million in the First Quarter

First-Quarter 2022 Results Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% Clinical Services revenue increased 2% to $99...

5 months ago - Accesswire

NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) ...

FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced toda...

5 months ago - Accesswire